Dear all;
I am just wondering whether any regulatory (FDA, MHRA etc. ) guidance
available on the starting dose of molecular targeted therapy (MTT) agents
such as tyrosine kinase inhibitors in cancer patients. I would appreciate
your thoughts on this topic.
Best regards,
VPokiri
>